Treatment of Pediatric Acute Lymphoblastic Leukemia and Recent Advances

Chang, Tai-Tsung; Lin, Pei‐Chin

doi:10.5772/26292

Cited by 2 publications

(2 citation statements)

References 119 publications

(92 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A mixture of anti-cancer medications is used in chemo for acute lymphocytic leukemia (ALL). They are normally delivered in three phases over the period of around two years 11 . Vincristine (Oncovin) or liposomal vincristine (Marqibo), Daunorubicin (Cerubidine) or doxorubicin (Adriamycin), Cytarabine (cytosine arabinoside, ara-C, or Cytosar), L-asparaginase (Elspar) or PEG-L-asparaginase (pegaspargase or Oncaspar), E (Decadron) People usually receive many of these medications at different periods throughout their treatment, but not all of them 12 .…”

Section: Chemotherapymentioning

confidence: 99%

Untitled

2022

IJPSR

View full text Add to dashboard Cite

The extracellular L-Asparaginase is an amidase group enzyme. In recent years enzymes gained greater importance in clinical research. The enzyme's capability to convert L-Asparagine into Aspartic acid and ammonia is the motivation after its anti-cancer action. ALL is a type of hematologic cancer that mainly affects children at the age of 2 to 10 years. L-asparaginase is a basic constituent of ALL and Hodgkin's lymphoma treatment. Because its foreword into pediatric treatment procedures in the 1960s, continued existence rates in children have steadily increased to almost 90%. Juvenile and adolescent patients diagnosed with ALL at the age group of 15-39 years have historically had poorer outcomes. Different diagnostic methods are available for ALL like blood tests, Bone marrow tests, Imaging tests and Spinal fluid tests. Apart from its medical applications, it is broadly used in the food industry to engage in acrylamide, a probable human carcinogen, and production in carbohydrate-rich foods cooked at high temperatures. L-Asparaginase plays an important role in the biosynthesis of the aspartic family of amino acids. L-Asparaginase has also been used to develop a diagnostic biosensor. INTRODUCTION:Cell morphology, immunophenotype, and genetics/cytogenetics are the established diagnostic criteria for acute lymphoblastic leukaemia (ALL), as specified in the 2008 WHO classification of lymphoid neoplasms 9 . In paediatric oncology, L-asparaginase is the prescribed medicine for acute lymphoblastic leukaemia therapy, with more than 90% of children recovering completely within four weeks.

show abstract

Section: Chemotherapymentioning

confidence: 99%

Untitled

2022

IJPSR

View full text Add to dashboard Cite

show abstract

“…Rapid progress in molecular biology has aided in the selection of patients with specific poor prognostic genetic factors, and sensitive monitoring of minimal residual disease (MRD) has also contributed significantly to the management of pediatric ALL ( 3 ). Previous studies have indicated that monitoring MRD constitutes an essential marker, and that detection of MRD, particularly at the end of induction and subsequent to treatment completion, was significantly predictive for the outcome of patients ( 4 , 5 ).…”

Section: Introductionmentioning

confidence: 99%

Gene set enrichment and topological analyses based on interaction networks in pediatric acute lymphoblastic leukemia

et al. 2015

View full text Add to dashboard Cite

Pediatric acute lymphoblastic leukemia (ALL) accounts for over one-quarter of all pediatric cancers. Interacting genes and proteins within the larger human gene interaction network of the human genome are rarely investigated by studies investigating pediatric ALL. In the present study, interaction networks were constructed using the empirical Bayesian approach and the Search Tool for the Retrieval of Interacting Genes/proteins database, based on the differentially-expressed (DE) genes in pediatric ALL, which were identified using the RankProd package. Enrichment analysis of the interaction network was performed using the network-based methods EnrichNet and PathExpand, which were compared with the traditional expression analysis systematic explored (EASE) method. In total, 398 DE genes were identified in pediatric ALL, and LIF was the most significantly DE gene. The co-expression network consisted of 272 nodes, which indicated genes and proteins, and 602 edges, which indicated the number of interactions adjacent to the node. Comparison between EASE and PathExpand revealed that PathExpand detected more pathways or processes that were closely associated with pediatric ALL compared with the EASE method. There were 294 nodes and 1,588 edges in the protein-protein interaction network, with the processes of hematopoietic cell lineage and porphyrin metabolism demonstrating a close association with pediatric ALL. Network enrichment analysis based on the PathExpand algorithm was revealed to be more powerful for the analysis of interaction networks in pediatric ALL compared with the EASE method. LIF and MLLT11 were identified as the most significantly DE genes in pediatric ALL. The process of hematopoietic cell lineage was the pathway most significantly associated with pediatric ALL.

show abstract

Treatment of Pediatric Acute Lymphoblastic Leukemia and Recent Advances

Cited by 2 publications

References 119 publications

Untitled

Untitled

Gene set enrichment and topological analyses based on interaction networks in pediatric acute lymphoblastic leukemia

Contact Info

Product

Resources

About